Royalty Pharma PLC (RPRX) Social Stream



Royalty Pharma PLC (RPRX): $38.96

0.06 (+0.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RPRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

ROYALTY PHARMA PLC (RPRX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering RPRX.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 8 $56.001 $46 $51.714 $38.33 34.92%
2022-02-02 7 $56 $46 $51.714 $38.33 34.92%
2022-03-08 7 $56 $46 $51.142 $38.33 33.43%
2022-04-06 7 $56 $48 $51.428 $38.33 34.17%
2022-05-06 7 $56 $48 $51.428 $38.33 34.17%
2022-06-09 9 $56 $48 $52.111 $38.33 35.95%
2022-06-14 10 $56 $47 $51.6 $38.33 34.62%
2022-08-03 10 $57 $47 $52.3 $38.33 36.45%
2022-10-12 10 $57 $47 $52.6 $38.33 37.23%
2022-10-27 10 $57 $47 $52.8 $38.33 37.75%
2022-11-28 9 $57 $47 $53.111 $38.33 38.56%
2022-12-06 9 $57 $47 $52.777 $38.33 37.69%
2023-01-10 9 $57 $47 $52.333 $38.33 36.53%

The Trend in the Analyst Price Target


RPRX's average price target has moved up $0.03 over the prior 160 days.

Over the past 50 weeks, RPRX's average upside potential has been 26.25%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-04-14 7 56 48 51.428 44.10 16.62%
2022-05-06 8 56 48 51.428 39.72 29.48%
2022-08-05 10 57 47 52.600 42.45 23.91%
2022-08-10 10 57 47 52.600 43.92 19.76%
2022-10-18 10 57 47 52.800 42.02 25.65%

RPRX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.17 7 2 0 0 0 9

The Trend in the Broker Recommendations


RPRX's average broker recommendation rating worsened by 0.02 over the prior 122 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • ROYALTY PHARMA PLC's variance in analysts' estimates is lower than -105.91% of all US stocks.
  • ROYALTY PHARMA PLC's number of analysts covering the stock is higher than 303% of stocks in the large market cap category.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ROYALTY PHARMA PLC's upside potential (average analyst target price relative to current price) is greater than 309.28% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ROYALTY PHARMA PLC's average analyst price target is higher than 919.17% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ROYALTY PHARMA PLC are CVAC, MRVI, and ABCL.

Make investment decisions regarding RPRX using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6175 seconds.